VEA
KNSA icon

Virtus ETF Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Virtus ETF Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,361
Closed -$343K – 620
2024
Q4 		$343K Sell
17,361
-195
-1% -$4.45K 0.14% 208
2024
Q3 		$439K Hold
17,556
– – 0.21% 192
2024
Q2 		$328K Sell
17,556
-4,791
-21% -$89.8K 0.16% 213
2024
Q1 		$441K Buy
22,347
+3,215
+17% +$62.8K 0.23% 186
2023
Q4 		$336K Buy
19,132
+671
+4% +$11K 0.21% 199
2023
Q3 		$321K Sell
18,461
-2,390
-11% -$40.3K 0.19% 196
2023
Q2 		$294K Buy
20,851
+1,155
+6% +$15.5K 0.17% 211
2023
Q1 		$212K Buy
19,696
+351
+2% +$4.62K 0.12% 304
2022
Q4 		$290K Sell
19,345
-9,062
-32% -$132K 0.15% 287
2022
Q3 		$365K Buy
28,407
+415
+1% +$4.73K 0.15% 244
2022
Q2 		$271K Sell
27,992
-2,029
-7% -$18.9K 0.1% 278
2022
Q1 		$298K Hold
30,021
– – 0.13% 177
2021
Q4 		$353K Buy
30,021
+12
+0% +$147 0.13% 181
2021
Q3 		$342K Sell
30,009
-2,753
-8% -$35.9K 0.15% 187
2021
Q2 		$456K Buy
32,762
+17,348
+113% +$264K 0.19% 179
2021
Q1 		$285K Buy
15,414
+266
+2% +$5.44K 0.12% 250
2020
Q4 		$268K Buy
15,148
+831
+6% +$14.6K 0.11% 285
2020
Q3 		$219K Sell
14,317
-1,957
-12% -$36.7K 0.11% 286
2020
Q2 		$415K Buy
+16,274
New +$340K 0.2% 186
2019
Q2 		– Sell
-11,763
Closed -$212K – 443
2019
Q1 		$212K Sell
11,763
-1,773
-13% -$34.2K 0.45% 86
2018
Q4 		$380K Buy
+13,536
New +$283K 0.06% 83

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus ETF Advisers's KNSA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 17,361 shares — an estimated $343K sold.

Virtus ETF Advisers first reported a position in KNSA in Q4 2018 and held it in 21 quarters. The position peaked at $456K in Q2 2021. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 17,361 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $343K.
  • Virtus ETF Advisers first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and held it in 21 quarters.
  • Virtus ETF Advisers's Kiniksa Pharmaceuticals position peaked at $456K in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.